| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥37.9B | ¥39.2B | -3.4% |
| Operating Income | ¥3.9B | ¥6.8B | -42.6% |
| Ordinary Income | ¥3.9B | ¥7.4B | -48.0% |
| Net Income | ¥2.8B | ¥5.2B | -45.9% |
| ROE | 4.7% | 8.9% | - |
FY2026 Q3 cumulative results show revenue of 37.9B yen (YoY -3.4%), operating income of 3.9B yen (YoY -42.6%), ordinary income of 3.9B yen (YoY -48.0%), and net income of 2.8B yen (YoY -45.9%). The company faces significant profitability deterioration with operating margin contracting to 10.2% from prior year 17.2%, representing a 700 basis point decline. Gross profit margin compressed to 40.0% from 43.3%, down 330 basis points year-over-year. The Tissue Culture segment demonstrated resilience with revenue growth to 19.2B yen, while Microbiological and Cell Process segments contracted. Corporate overhead allocation increased to 4.4B yen from 4.0B yen, further pressuring segment profitability. Net profit margin deteriorated to 7.4% from 13.2%, driving ROE down to 4.7% from prior levels. This marks a clear inflection point with simultaneous revenue decline and margin compression.
Revenue declined 3.4% to 37.9B yen, driven by mixed segment performance. The Tissue Culture segment grew 13.4% to 19.2B yen from 16.9B yen, representing the primary growth driver and accounting for 50.7% of total revenue. However, this was offset by Microbiological segment contraction of 18.0% to 10.9B yen from 13.2B yen, and Cell Process segment decline of 13.4% to 7.8B yen from 9.0B yen. The revenue composition shift toward the higher-margin Tissue Culture business was insufficient to offset overall volume and pricing pressures.
Profitability deterioration was more severe than revenue decline. Operating income fell 42.6% to 3.9B yen from 6.8B yen, reflecting both margin compression and increased costs. Gross profit decreased 15.2% to 15.2B yen from 17.9B yen, with gross margin contracting 330 basis points. Cost of sales rose as a percentage of revenue to 60.0% from 56.7%, suggesting input cost inflation or unfavorable product mix. SG&A expenses increased in absolute terms to 11.3B yen from 10.3B yen despite revenue decline, representing 29.8% of sales versus 26.2% prior year. The segment notes indicate corporate overhead allocation increased to 4.4B yen from 4.0B yen, representing unallocated general and administrative expenses that disproportionately impacted overall profitability.
Ordinary income declined 48.0% to 3.9B yen from 7.4B yen, slightly underperforming operating income due to net non-operating expense of 0.04B yen. Non-operating income of 0.5B yen included equity method income of 0.3B yen, offset by non-operating expenses of 0.5B yen including interest expense of 0.3B yen. Net income fell 45.9% to 2.8B yen from 5.2B yen, with the decline broadly aligned with ordinary income deterioration. Income tax expense of 1.1B yen represented an effective tax rate of 28.2%, consistent with prior year. Extraordinary items were minimal with extraordinary income of 0.1B yen offset by extraordinary loss of 0.1B yen from asset disposals.
This represents a revenue down, profit down pattern, characterized by simultaneous top-line contraction and accelerated margin erosion driven by unfavorable operating leverage and cost structure rigidity.
The Tissue Culture segment generated revenue of 19.2B yen and operating income of 7.4B yen with a margin of 38.4%, representing the core business by both revenue share (50.7%) and profitability contribution. This segment demonstrated strong resilience with 13.4% revenue growth and maintained industry-leading margins, serving as the primary earnings engine despite overall corporate challenges.
The Microbiological segment reported revenue of 10.9B yen with operating loss of 0.2B yen, resulting in negative margin of 1.4%. This segment experienced the steepest revenue decline of 18.0% and shifted from profitability to loss, indicating acute operational challenges potentially related to demand weakness or competitive pressures in the microbiological testing market.
The Cell Process segment recorded revenue of 7.8B yen with operating income of 1.0B yen and margin of 12.6%. While maintaining profitability, this segment contracted 13.4% in revenue, reflecting challenges in scaling specialized cell processing services. The margin of 12.6% positions it between the high-margin Tissue Culture business and loss-making Microbiological operations.
Segment margin disparity is material, with 39.8 percentage points separating the Tissue Culture segment from Microbiological operations. Corporate overhead allocation of 4.4B yen represents 11.5% of total revenue, with the increase of 9.6% year-over-year outpacing any segment revenue growth and contributing significantly to consolidated margin compression.
[Profitability] ROE of 4.7% declined from higher prior year levels, driven primarily by net profit margin compression to 7.4% representing 742 basis points of deterioration. Operating margin of 10.2% contracted 700 basis points from 17.2%, marking significant profitability erosion. Gross profit margin of 40.0% declined 330 basis points from 43.3%, indicating pricing pressure or cost inflation. The company's operating margin of 10.2% compares to prior performance but represents substantial deterioration requiring operational intervention. [Efficiency] Asset turnover of 0.42 times reflects capital intensity in manufacturing operations. Inventory turnover extended to 144 days from more efficient prior levels, indicating working capital deterioration. Receivables turnover reached 77 days while payables turnover was 32 days, resulting in cash conversion cycle of 189 days, substantially elevated from historical norms and indicating working capital management challenges. [Financial Health] Equity ratio of 66.0% reflects conservative capitalization with total equity of 59.2B yen supporting total assets of 89.6B yen. Current ratio of 186.0% and quick ratio of 174.4% indicate adequate short-term liquidity on surface metrics. However, cash and deposits of 22.7B yen declined 28.0% from 31.5B yen prior year, representing material liquidity reduction. Short-term borrowings of 15.0B yen against declining cash reserves warrant monitoring. Debt-to-equity ratio of 0.30 times remains conservative with total interest-bearing debt of 17.6B yen. Interest coverage ratio of 13.7 times provides comfortable debt service capacity. [Cash Quality] The substantial deterioration in working capital metrics with inventory days of 144, receivables days of 77, and cash conversion cycle of 189 days indicates earnings quality concerns as profits are not efficiently converting to cash.
Cash and deposits decreased 8.8B yen to 22.7B yen from 31.5B yen prior year, representing a 28.0% decline and the most significant balance sheet movement. This substantial cash reduction occurred despite positive net income of 2.8B yen, indicating material cash consumption from operations or investing activities. Working capital deterioration is evident with inventory increasing to support 144 days of sales while receivables extended to 77 days, collectively absorbing liquidity. Trade payables increased 49.2% to 2.0B yen from 1.3B yen, suggesting extended payment terms to preserve cash, though the absolute amount remains modest relative to payables turnover of 32 days. Long-term borrowings decreased 30.0% to 2.6B yen from 3.8B yen, indicating 1.1B yen of debt repayment, while short-term borrowings remained at 15.0B yen, shifting debt composition toward shorter maturities. The combination of declining cash, extended working capital cycle with CCC of 189 days, and debt service represents a tightening liquidity profile requiring careful monitoring. Property, plant and equipment of 37.6B yen remained the largest asset category, suggesting ongoing capital intensity, while the cash coverage of short-term borrowings declined to 1.51 times from more comfortable prior levels.
Ordinary income of 3.9B yen compared to operating income of 3.9B yen indicates minimal net non-operating impact of approximately 0.04B yen negative contribution. Non-operating income of 0.5B yen comprised equity method income of 0.3B yen and other financial income, offset by non-operating expenses of 0.5B yen including interest expense of 0.3B yen and other costs. Non-operating items represent 1.3% of revenue on a net basis, maintaining limited influence on core operating performance. Extraordinary items totaled 0.1B yen gain and 0.1B yen loss, netting to immaterial impact with the loss primarily from asset disposal of 0.1B yen. The profit structure remains predominantly driven by operating performance without material non-recurring distortions. However, earnings quality concerns emerge from working capital deterioration with cash conversion cycle expanding to 189 days from healthier prior levels, indicating profits are not efficiently converting to cash. The 28.0% decline in cash and deposits despite positive net income, combined with inventory days of 144 and receivables days of 77, suggests significant cash absorption in working capital. While extraordinary items do not distort reported earnings, the underlying cash generation quality has materially deteriorated, requiring operational improvements in inventory management and receivables collection to restore earnings quality.
Full-year guidance projects revenue of 49.7B yen (YoY -4.5%), operating income of 4.6B yen (YoY -53.1%), ordinary income of 4.7B yen (YoY -56.1%), and net income of 3.4B yen with EPS forecast of 65.65 yen. Q3 cumulative progress shows revenue achievement of 76.2% against full-year guidance, which is 1.2 percentage points behind the standard 75% quarterly run rate, indicating modest underperformance. Operating income progress of 83.5% is 8.5 percentage points ahead of the 75% standard benchmark, suggesting stronger-than-expected Q3 performance or anticipated Q4 headwinds. The company revised both earnings and dividend forecasts during the quarter, though specific revision details were not quantified in the available data. Full-year dividend forecast of 10.00 yen represents a significant reduction from the 24.00 yen interim indication, suggesting conservative capital allocation aligned with profitability challenges. The guidance assumes continued pressure on profitability metrics with operating margin projected at 9.3% for the full year compared to 10.2% achieved through Q3, implying Q4 margin of approximately 6.4% if guidance is maintained. Given the working capital deterioration and cash consumption trends observed through Q3, achievement of full-year guidance will depend critically on Q4 working capital normalization and cost control execution.
Annual dividend forecast is 10.00 yen per share for the full fiscal year, compared to the 24.00 yen per share indicated for the interim period in the balance sheet equity section. Based on the forecast net income of 3.4B yen and annual dividend of 10.00 yen on 5,112 thousand shares outstanding, the implied total dividend payment of 0.5B yen represents a payout ratio of 15.2% against forecast earnings. This is substantially lower than the 44.0% payout ratio calculated from the 24.00 yen per share interim indication, suggesting the company revised dividend policy downward in response to profitability challenges. The conservative payout ratio of 15.2% provides significant retained earnings for operational needs, particularly relevant given the 28.0% decline in cash and deposits and working capital pressures observed through Q3. No share buyback program was disclosed in the available data. The total shareholder return ratio equals the payout ratio of 15.2% in the absence of buybacks. The dividend reduction from earlier 24.00 yen indication to 10.00 yen forecast represents a strategic shift toward cash preservation, appropriate given liquidity pressures and the need to fund 189-day cash conversion cycle. While the lower payout ratio is sustainable from an earnings coverage perspective, the dividend cut may signal management concern about cash flow sustainability until working capital efficiency improves.
Segment concentration risk in Tissue Culture business representing 50.7% of revenue with 38.4% margin means any disruption to this core segment would materially impact consolidated performance. The Microbiological segment operating loss of 0.2B yen on revenue decline of 18.0% indicates acute challenges in this business line, with risk of further deterioration or restructuring requirements if market conditions do not improve. Working capital management represents the most quantifiable operational risk, with cash conversion cycle extended to 189 days comprising inventory turnover of 144 days and receivables of 77 days, absorbing substantial liquidity. The 28.0% year-over-year decline in cash and deposits to 22.7B yen while maintaining 15.0B yen in short-term borrowings creates refinancing risk, with cash coverage of short-term debt declining to 1.51 times. Short-term liabilities represent 85.1% of total liabilities, indicating concentrated maturity risk that requires active management, particularly given declining cash reserves. Corporate overhead allocation increased 9.6% to 4.4B yen despite revenue contraction, indicating cost structure rigidity that pressures margins during periods of revenue volatility. The combination of deteriorating profitability with operating margin compressed 700 basis points to 10.2%, increasing fixed cost burden, and working capital inefficiency creates compounding pressure on cash generation and financial flexibility.
[Industry Position] (Reference - Proprietary Analysis)
The company's profitability metrics show weakness relative to industry standards. ROE of 4.7% falls below the manufacturing industry median of 5.8% for 2025-Q3, positioning in the lower half of peer performance. Operating margin of 10.2% exceeds the industry median of 8.9%, though this represents significant deterioration from the company's prior 17.2% and the current margin includes distortion from loss-making segments offset by high-margin Tissue Culture operations. Net profit margin of 7.4% slightly exceeds the industry median of 6.5%, but declined from 13.2% prior year, indicating faster margin erosion than peer average.
Financial health metrics remain strong relative to benchmarks. Equity ratio of 66.0% exceeds the industry median of 63.8%, reflecting conservative capitalization. Current ratio of 186.0% is below the industry median of 287.0%, indicating relatively higher working capital efficiency on surface metrics, though this is contradicted by the company's elevated cash conversion cycle. Financial leverage of 1.51 times aligns closely with the industry median of 1.53 times.
Efficiency metrics reveal significant underperformance. Asset turnover of 0.42 times falls well below the industry median of 0.56 times, indicating lower revenue generation per unit of assets. Working capital metrics show substantial deterioration with inventory turnover of 144 days significantly exceeding the industry median of 112 days, indicating excess inventory or slower turnover. Receivables turnover of 77 days compares to industry median of 85 days, showing relative strength in collections despite absolute deterioration. Cash conversion cycle of 189 days substantially exceeds calculated industry benchmarks, representing a key area of competitive disadvantage.
Growth performance lags peers significantly. Revenue decline of 3.4% compares unfavorably to industry median growth of 2.8%, positioning the company in revenue contraction while peers demonstrate expansion. The operating margin deterioration and revenue decline combination represents weaker relative positioning than median peer performance.
(Industry: Manufacturing, Comparison: 2025-Q3 medians, Source: Proprietary Analysis, Sample size: 84-105 companies depending on metric)
Significant margin compression represents the most critical trend, with operating margin contracting 700 basis points to 10.2% from 17.2% and net profit margin declining 742 basis points to 7.4%, indicating structural profitability challenges requiring operational intervention rather than temporary cyclical pressure. The simultaneous revenue decline of 3.4% and accelerated profit decline of 42.6% to 45.9% across operating, ordinary, and net income demonstrates negative operating leverage from fixed cost structure. Working capital deterioration represents a structural cash flow headwind, with cash conversion cycle extending to 189 days driven by inventory days of 144 and receivables days of 77, absorbing liquidity and indicating potential demand softness or operational inefficiency. The 28.0% reduction in cash and deposits to 22.7B yen while maintaining 15.0B yen in short-term borrowings represents a material shift in liquidity profile, with cash coverage of short-term debt declining to 1.51 times from more comfortable prior levels, warranting monitoring of refinancing requirements and debt service capacity. Dividend policy recalibration from 24.00 yen interim indication to 10.00 yen annual forecast demonstrates management prioritization of cash preservation over shareholder distributions, appropriate given liquidity pressures but signaling concern about near-term cash generation sustainability. The Tissue Culture segment growth of 13.4% with 38.4% margin provides a positive foundation, accounting for over half of revenue and maintaining strong profitability, though this is offset by Microbiological segment shift to operating loss and Cell Process contraction. Full-year guidance implies Q4 operating margin compression to approximately 6.4% if maintained, suggesting management anticipates continued profitability pressure rather than recovery in the fiscal year-end quarter.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.